|
|
|
|
Gamma delta T cells are well suited for a wide variety of treatments due to their reduced risk of graft-versus-host disease, enhancing their overall safety profile. Dr. Zhang highlights two unique methods for clinical scale expansion: zoledronic acid activation and anti-CD3/CD28 activation.
|
|
|
|
|
TheraPEAK® T-VIVO® Cell Culture Medium, featuring only recombinant proteins and no animal-derived components, simplifies the CAR-T cell therapy manufacturing process. It supports superior T-cell expansion, outperforming other commercially available media.
|
|
|
|
|
This E-Book explores essential cellular assays for safe drug discovery, explains the use of primary cells in testing immune effects, highlights key factors like donor diversity and HLA-typing, and discusses emerging cellular application trends in the immuno-oncology field.
|
|
|
|
|
Researchers have trusted the 4D-Nucleofector® LV Unit to efficiently modify large volumes of cells in their non-viral, ex vivo cell and gene therapy processes. With this overview on selected publications, we aim to provide insights into these researchers' work and achievements.
|
|
|
|
|
To address multiple pain points, complementary technologies were combined to enable non-viral gene delivery for cell immunotherapy manufacturing in a functionally-closed, automated workflow. The study objective was to demonstrate their ability to modify primary T cells.
|
|
|
